The national scale: about 24 infants a year in England and Wales, about 12 in Australia
also called UK infant leukemia cases per year · Australia infant leukaemia numbers
England and Wales record about 595,000 births a year and Australia about 292,000, so at the US infant leukemia rate they should see roughly 24 and 12 infant acute leukemia cases a year respectively. Australia therefore diagnoses about five infants a year with KMT2A-rearranged leukemia, which is the entire national population a trial could draw on.
The same thing, for a scientist
Applying the US infant acute leukemia incidence of ~41 per million infants per year to national birth counts gives ~24 infant acute leukemia cases per year in England and Wales (594,677 live births in 2024) and ~12 in Australia (292,318 registered births in 2024). Decomposed with the standard lineage split and KMT2A frequencies, that is roughly 10-11 KMT2A-rearranged infant ALL cases per year in England and Wales and 5 in Australia. These are not registry counts; they are rate-times-denominator constructions, and their value is in making the trial-design problem concrete rather than in being precise.
The denominators, stated first2 deeper
Denominator: live births registered in one calendar year in each jurisdiction 12. Births are a proxy for infant person-years at risk; infant mortality from other causes makes them a slight over-estimate.
| Jurisdiction | Live births, 2024 | Implied infant acute leukemia cases/yr | Implied infant ALL | Implied KMT2A-r infant ALL |
|---|---|---|---|---|
| England and Wales | 594,677 1 | ~24 | ~14 | ~10-11 |
| Australia | 292,318 2 | ~12 | ~7 | ~5 |
| United States (for comparison) | — | ~160 3 | ~90 | ~63-72 |
Scotland and Northern Ireland are not included in the England and Wales figure, so whole-UK counts are perhaps 10% higher. The Australian figure is registered births, which lag occurrence slightly.
What five cases a year means for a trial
Australia diagnoses on the order of five infants a year with KMT2A-rearranged ALL. A two-arm randomised trial needing 100 infants per arm would take, at full national capture with no exclusions and no refusals, forty years.
This is the concrete form of the platform problem. It is why the Interfant consortium exists, why trialdesign-external-and-historical-controls-infant and trialdesign-bayesian-borrowing-across-fusions are not statistical exotica but the only options, and why the blinatumomab infant study was a 30-patient single-arm study against historical controls rather than a randomised trial 4.
Why these are constructions and not counts
Both England and Wales and Australia have high-quality childhood cancer registration, so real counts exist; what is not published in a form this beat could verify is an infant-specific, KMT2A-stratified annual count. The national childhood cancer registries could supply one on request, and doing so would replace these derived numbers with measured ones. Until then every figure in the table above inherits the uncertainty of the US rate it was built from, and should be quoted as 'of the order of', not as a count.
| metric | derived annual case count |
|---|---|
| value | 24 |
| unit | infant acute leukemia cases per year |
| population | infants under 1 year |
| region | England and Wales |
| year | 2024 |
| source | derived: ONS 2024 live births x US infant incidence (Brown 2013) |
| denominator | 594,677 live births in England and Wales in 2024 |
jurisdictions — the numbers behind the chart
[
{
"region": "England and Wales",
"births_2024": 594677,
"infant_acute_leukemia_per_year": 24,
"infant_all_per_year": 14,
"kmt2a_r_infant_all_per_year": [
10,
11
]
},
{
"region": "Australia",
"births_2024": 292318,
"infant_acute_leukemia_per_year": 12,
"infant_all_per_year": 7,
"kmt2a_r_infant_all_per_year": 5
},
{
"region": "United States",
"births_2024": null,
"infant_acute_leukemia_per_year": 160,
"infant_all_per_year": 90,
"kmt2a_r_infant_all_per_year": [
63,
72
]
}
]- Presenting derived national counts as if they were registry counts is the easiest way to lose credibility with a national trials group who know their own accrual numbers. Always say 'implied by the US rate'.
- A country with five eligible infants a year cannot ethically run a competing trial against an international consortium; proposing one would fragment the only accrual pool that exists.
- Will the UK National Disease Registration Service and the Australian Childhood Cancer Registry release infant-specific, KMT2A-stratified annual counts, which would replace every derived figure here?
- Do UK and Australian infant leukemia rates actually match the US rate, or is there a real national difference that these constructions hide?
- E1established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.dataset
There were 594,677 live births in England and Wales in 2024, an increase of 3,605 (0.6%) on the 591,072 live births in 2023 and the first increase since 2021.
Births in England and Wales: 2024 · Office for National Statistics · Office for National Statistics 2025What this evidence cannot show
Covers England and Wales only, not Scotland or Northern Ireland. Fertility rates for 2024 were not calculated in this release because mid-year population estimates were unavailable.
Evidence that argues against this (1)
- A live-birth count is the certain half of the calculation and the uncertain half is the incidence rate applied to it. Infant KMT2A-rearranged leukaemia produces a few dozen cases a year in a country this size, so Poisson variation dominates any year-on-year change, and birth registrations are themselves revised after first publication. Statistics in Medicine 2006
- E2established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.dataset
There were 292,318 registered births in Australia in 2024, an increase of 1.9% (5,320 births) on 2023, with a total fertility rate of 1.481.
Births, Australia, 2024 · Australian Bureau of Statistics · Australian Bureau of Statistics 2025What this evidence cannot show
Registered births, which lag births by a variable interval, so a single year's registrations is not exactly that year's births.
Evidence that argues against this (1)
- The same applies, plus an ascertainment difference: infant leukaemia diagnosis depends on karyotype, FISH and molecular testing whose availability differs between health systems, so a case count derived from births is bounded by how completely each country detects the rearrangement. Blood Cells, Molecules and Diseases 2010
- E3strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.review
US infant acute leukemia incidence is about 41 per million infants per year, roughly 160 US cases annually (~90 ALL, ~70 AML), with KMT2A rearrangement in 70-80% of infant ALL.
Treatment of infant leukemias: challenge and promise · Brown P · Hematology Am Soc Hematol Educ Program 2013What this evidence cannot show
A US rate from 2013 transplanted onto UK and Australian denominators; no infant-specific UK or Australian rate was verified for this entry.
Evidence that argues against this (2)
- A consistency check that the derived per-country figures fail. This entry derives roughly 10-11 KMT2A-rearranged infant ALL cases per year in England and Wales and 5 in Australia. The consortium protocol that exists to enrol exactly those children, Interfant-21 (NCT05327894), plans 160 KMT2A-rearranged infants across 24 countries between 2022-12-15 and a primary completion date of 2027-09 -- about 33 per year for the whole consortium. On this entry's numbers Australia alone would contribute about 15% of the world consortium's annual accrual, and England and Wales about a third, which is not credible. Either the derived national rates are too high, or consortium accrual captures only a minority of diagnosed infants -- and both possibilities matter for `ana-infant-trial-feasibility-arithmetic`. Read from the ClinicalTrials.gov API v2 record on 2026-09-18. Princess Maxima Center for Pediatric Oncology 2026
- Searched and not found, recorded as a finding: no published infant-specific (under one year) leukaemia incidence rate for the United Kingdom or Australia was located on 2026-09-18 via PubMed searches on infant leukaemia incidence combined with registry, United Kingdom and under-one-year terms. The entry's transplanted US rate therefore remains unchecked against a national source, and the entry is right to flag it. A separate registry observation that should be verified rather than assumed: the ClinicalTrials.gov location list for Interfant-21 names Argentina, Australia, Austria, Belgium, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Norway, Portugal, Saudi Arabia, Slovakia, Spain and Sweden, and does not name the United Kingdom. Registry location lists are not always complete or current, so this is a prompt to check with the UK consortium, not a conclusion that UK infants are outside the protocol. Princess Maxima Center for Pediatric Oncology (record); US National Library of Medicine (registry) 2026
- E4established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.paper
The blinatumomab infant study enrolled 30 newly diagnosed infants in a single-arm design compared against historical Interfant-06 controls, because a randomised design in this population was not feasible.
Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia · van der Sluis IM, de Lorenzo P, Kotecha RS, et al. · New England Journal of Medicine 2023What this evidence cannot show
The paper does not state infeasibility of randomisation as its explicit rationale; the inference that 30 patients and historical controls reflect accrual constraints is this node's reading, though it is the standard reading in paediatric oncology. **Regraded strong -> established on 2026-09-20** under `concept-the-confidence-grading-rule`: this is the trial's own reported result, which is established as a fact about what the trial found.
Evidence that argues against this (1)
- The inference that 30 patients and historical controls reflect an infeasibility of randomisation, which this evidence item flags as the node's own reading, is now contradicted by practice. NCT06317662 (National Cancer Institute, RECRUITING since 2025-06-05) is a frontline infant ALL study with maximum age 365 days, allocation RANDOMIZED and planned enrolment 153, randomising the KMT2A-rearranged patients to the addition of venetoclax, across US and Puerto Rico sites only. Randomisation in newly diagnosed infants is being attempted at a scale five times the blinatumomab study, in one country. Read from the ClinicalTrials.gov API v2 record on 2026-09-18. National Cancer Institute (NCI) 2026
Counter-evidence (Interfant-21 NCT05327894, read 2026-09-18): this entry's derived national rates would make Australia ~15% and England and Wales ~a third of the entire 24-country consortium's annual KMT2A-rearranged infant accrual (~33/yr). Either the derived rates are too high or consortium accrual captures a minority of diagnosed infants; both change the feasibility arithmetic.
national decomposition of the global estimate
- supports →Interfant-06 — 651 infants, and the definitive answer that myeloid-style consolidation does not help
five cases a year nationally forces consortium trials
- ← related toThe EU paediatric investigation plan: an obligation, not an incentive - and the deferral is the loophole
the European populations a PIP would cover